60 Degrees Pharmaceuticals, Inc. (SXTP) Sets January 2027 Data Readout, Plans FDA Pre-sNDA Meeting
60 Degrees Pharmaceuticals (SXTP) will unblind its 30-patient severe babesiosis trial and report results in January 2027. The company plans to request a pre-sNDA meeting with the FDA that month to discuss a potential regulatory pathway, including accelerated approval based on NAT clearance. The trial enrollment was concluded early due to seasonal factors and limited statistical power gains from additional patients.
How this was made
The 30-second read
Why it matters
The scheduled January 2027 readout provides a clear timeline for investors, but the ultimate market move will depend on efficacy signals and FDA feedback.
Market read
Creates a near‑term catalyst for a micro‑cap biotech; relevance tied to upcoming data and regulatory path.
What to watch
Potential competition from alternative treatments and the need for larger pivotal trials.
Background
60 Degrees Pharmaceuticals is a clinical‑stage biotech focused on tafenoquine‑based treatments for severe babesiosis.
Ticker impact
Company announced a January 2027 readout of its severe babesiosis trial and will request a pre-sNDA meeting with the FDA.
potential upside if trial data meet expectations and FDA pathway is favorable; downside risk if data disappoint.
No safety signals were reported, but the small sample size adds uncertainty; the market will price in the January 2027 outcome.
Market effects
May influence other biotech firms developing tafenoquine or severe babesiosis therapies.
Limited to U.S. biotech sector.
Low; primarily affects niche infectious‑disease biotech investors.
Counterpoint
The small trial size could limit regulatory enthusiasm, making the catalyst less impactful.
Key entities
- company60 Degrees Pharmaceuticals, Inc.
Biotech developing tafenoquine regimens for severe babesiosis.
